Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignancy: Myeloma - the Elusive Cure.

M. L. Smith1, S. M. Kelsey

  • 1Dept. of Haematology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK.

Hematology (Amsterdam, Netherlands)
|June 16, 2001
PubMed
Summary

Multiple myeloma, a plasma cell malignancy, is largely incurable. Current treatments like melphalan offer improved survival, but advanced therapies and palliative care are crucial for managing this aggressive cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

The role of von Willebrand factor in gastrointestinal angiodysplasia and obscure gi bleeding: a narrative review.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Temporal trends and global comparison of the burden of thalassemia in China: an analysis of the Global Burden Of Disease Study 2021.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Integrated multi-omics analysis identifies prognostic risk genes and constructs a predictive signature in diffuse large B-cell lymphoma.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026

Area of Science:

  • Hematology
  • Oncology

Background:

  • Multiple myeloma is a plasma cell malignancy accounting for 1% of all cancers.
  • It is characterized by malignant plasma cell expansion and is typically incurable with a median survival of 6 months untreated.

Purpose of the Study:

  • To review current treatment strategies for multiple myeloma.
  • To discuss the efficacy and limitations of various therapeutic approaches, including chemotherapy, stem cell transplantation, and experimental treatments.

Main Methods:

  • Review of existing literature on multiple myeloma treatments.
  • Analysis of single-agent therapies (melphalan), combination chemotherapy, dose escalation, stem cell support (autografting, allogeneic transplantation), and emerging therapies (interferon alpha, P-gp inhibition, thalidomide).

Main Results:

  • Oral melphalan, alone or with steroids, is the gold standard, improving median survival to approximately 36 months in 40% of patients.
  • Significant melphalan dose escalation increases response rates but also toxicity, partially mitigated by stem cell support.
  • Autografting shows potential but is not curative; allogeneic transplantation is limited to a few patients due to high mortality. Interferon alpha has minimal impact on overall survival.

Conclusions:

  • While treatments like melphalan improve survival, multiple myeloma remains largely incurable.
  • Advanced therapies and stem cell support offer benefits but have limitations.
  • Palliative care, focusing on managing complications like renal failure, anemia, infection, hypercalcemia, and bone disease, is essential for many patients.

Related Experiment Videos